Adoptive allogeneic immunotherapy--history and future perspectives.
For more than 30 yrs allogeneic hematopoietic stem cell transplantations have been successfully performed in patients with hematologic malignancies and bone marrow aplasia. Over the years the field of transplantation has changed dramatically. More and more unrelated donors became available, regimens for haploidentical transplantations were introduced and G-CSF mobilized peripheral blood stem cells and fetal cells from umbilical cord became available as alternate sources of hematopoietic stem cells. However, especially the introduction of donor lymphocyte infusions (DLI) for the successful treatment of leukemic relapses after allogeneic stem cell transplantations improved our understanding of transplantation immunology and opened amazing perspectives in allogeneic transplantation. It was long believed, that myeloablative therapy with high-dose chemotherapy and total body irradiation (TBI) are the sole antileukemic principles in allogeneic transplantations. But by now it became clear, that donor lymphocytes exert a very potent antileukemic effect, now referred as the graft-versus-leukemia (GVL) or graft-versus-malignancy (GVM) reaction. The efficacy of DLI in controlling leukemic relapses suggests that myeloablative therapy is not essential for long-term disease control. By exploiting the GVL or GVM reaction more intensively the role of chemotherapy and TBI is changing to immunosuppression. Sufficient immunosuppression to allow grafting, however, can be achieved with much lower doses as those which have been used in conventional transplants. Therefore allogeneic transplants have become also available for the elderly or for patients with concurrent medical conditions, which would have excluded them from conventional transplants. Moreover, this allogeneic transplantation strategy with reduced intensity conditioning is now also under investigation in patients with susceptible solid tumors and autoimmune diseases. However, one major obstacle in allogeneic transplantations, namely the graft-versus-host disease (GVHD), remains to be solved.
Schleuning
M
M
Med. Klinik III, Universitätsklinikum Grosshadern, Marchiouiuistrasse 15, 81377, Munchen, Germany. mschleu@lrz.uni-muenchen.de
D000328:Adult; D000368:Aged; D000741:Anemia, Aplastic / Q000209:etiology; D000818:Animals; D002986:Clinical Trials as Topic; D016207:Cytokines / Q000627:therapeutic use; D004285:Dogs; D005240:Feasibility Studies; D005260:Female; D005312:Fetal Blood / Q000166:cytology; D005544:Forecasting; D015316:Genetic Therapy; D006086:Graft vs Host Disease / Q000209:etiology / Q000517:prevention & control; D020544:Graft vs Leukemia Effect; D016179:Granulocyte Colony-Stimulating Factor / Q000494:pharmacology; D019337:Hematologic Neoplasms / Q000097:blood / Q000276:immunology / Q000628:therapy; D019650:Hematopoietic Stem Cell Mobilization; D018380:Hematopoietic Stem Cell Transplantation / Q000009:adverse effects / Q000379:methods; D006648:Histocompatibility; D006801:Humans; D016219:Immunotherapy, Adoptive / Q000639:trends; D007231:Infant, Newborn; D007942:Leukemia, Experimental / Q000628:therapy; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000628:therapy; D017708:Leukocyte Transfusion; D008297:Male; D051379:Mice; D008875:Middle Aged; D023421:Models, Animal; D012008:Recurrence; D012074:Remission Induction; D016879:Salvage Therapy; D013602:T-Lymphocytes, Cytotoxic / Q000276:immunology / Q000637:transplantation; D019172:Transplantation Conditioning / Q000009:adverse effects
D016207:Cytokines; D016179:Granulocyte Colony-Stimulating Factor